172 related articles for article (PubMed ID: 25343963)
1. Adjuvant therapy with high dose vitamin D following primary treatment of melanoma at high risk of recurrence: a placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D).
Saw RP; Armstrong BK; Mason RS; Morton RL; Shannon KF; Spillane AJ; Stretch JR; Thompson JF
BMC Cancer; 2014 Oct; 14():780. PubMed ID: 25343963
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial.
De Smedt J; Van Kelst S; Boecxstaens V; Stas M; Bogaerts K; Vanderschueren D; Aura C; Vandenberghe K; Lambrechts D; Wolter P; Bechter O; Nikkels A; Strobbe T; Emri G; Marasigan V; Garmyn M
BMC Cancer; 2017 Aug; 17(1):562. PubMed ID: 28835228
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
[TBL] [Abstract][Full Text] [Related]
4. A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients.
Mao L; Si L; Chi Z; Cui C; Sheng X; Li S; Tang B; Guo J
Eur J Cancer; 2011 Jul; 47(10):1498-503. PubMed ID: 21493058
[TBL] [Abstract][Full Text] [Related]
5. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
Richtig E; Soyer HP; Posch M; Mossbacher U; Bauer P; Teban L; Svolba G; Wolf IH; Fritsch P; Zelger B; Volc-Platzer B; Gebhart W; Mischer P; Steiner A; Pachinger W; Hintner H; Gschnait F; Rappersberger K; Pilarski P; Pehamberger H;
J Clin Oncol; 2005 Dec; 23(34):8655-63. PubMed ID: 16260701
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant and neoadjuvant therapy for gastric cancer.
Kelsen DP
Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
[TBL] [Abstract][Full Text] [Related]
7. Patterns of failure following surgical resection for malignant pleural mesothelioma.
Jänne PA; Baldini EH
Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
[TBL] [Abstract][Full Text] [Related]
8. Australian multi-center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma.
Coventry BJ; Kroon HM; Giles MH; Henderson M; Speakman D; Wall M; Barbour A; Serpell J; Paddle P; Coventry AG; Sullivan T; Smithers BM
J Surg Oncol; 2014 Jun; 109(8):780-5. PubMed ID: 24634160
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
Augustin M; Bock PR; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2005; 55(1):38-49. PubMed ID: 15727163
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
[TBL] [Abstract][Full Text] [Related]
11. 25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial.
Lipplaa A; Fernandes R; Marshall A; Lorigan P; Dunn J; Myers KA; Barker E; Newton-Bishop J; Middleton MR; Corrie PG
Br J Cancer; 2018 Oct; 119(7):793-800. PubMed ID: 30033445
[TBL] [Abstract][Full Text] [Related]
12. [Malignant melanoma].
Matsumoto K; Saida T
Nihon Rinsho; 2006 Jul; 64(7):1321-6. PubMed ID: 16838651
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial.
Stadler R; Luger T; Bieber T; Köhler U; Linse R; Technau K; Schubert R; Schroth K; Vakilzadeh F; Volkenandt M; Gollnick H; Von Eick H; Thoren F; Strannegård O
Acta Oncol; 2006; 45(4):389-99. PubMed ID: 16760174
[TBL] [Abstract][Full Text] [Related]
14. Randomised clinical trial of adjuvant postoperative RT vs. sequential postoperative RT plus 5-FU and levamisole in patients with stage II-III resectable rectal cancer: a final report.
Cafiero F; Gipponi M; Lionetto R;
J Surg Oncol; 2003 Jul; 83(3):140-6. PubMed ID: 12827681
[TBL] [Abstract][Full Text] [Related]
15. High-dose vitamin D supplementation to prevent prostate cancer progression in localised cases with low-to-intermediate risk of progression on active surveillance (ProsD): protocol of a phase II randomised controlled trial.
Nair-Shalliker V; Smith DP; Gebski V; Patel MI; Frydenberg M; Yaxley JW; Gardiner R; Espinoza D; Kimlin MG; Fenech M; Gillatt D; Woo H; Armstrong BK; Rasiah K; Awad N; Symons J; Gurney H
BMJ Open; 2021 Mar; 11(3):e044055. PubMed ID: 33653757
[TBL] [Abstract][Full Text] [Related]
16. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
Bunn PA
Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
[TBL] [Abstract][Full Text] [Related]
17. Primary mucosal melanoma of the head and neck. Comparison of clinical presentation and histopathologic features of oral and sinonasal melanoma.
McLean N; Tighiouart M; Muller S
Oral Oncol; 2008 Nov; 44(11):1039-46. PubMed ID: 18396446
[TBL] [Abstract][Full Text] [Related]
18. Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.
Slingluff CL; Lewis KD; Andtbacka R; Hyngstrom J; Milhem M; Markovic SN; Bowles T; Hamid O; Hernandez-Aya L; Claveau J; Jang S; Philips P; Holtan SG; Shaheen MF; Curti B; Schmidt W; Butler MO; Paramo J; Lutzky J; Padmanabhan A; Thomas S; Milton D; Pecora A; Sato T; Hsueh E; Badarinath S; Keech J; Kalmadi S; Kumar P; Weber R; Levine E; Berger A; Bar A; Beck JT; Travers JB; Mihalcioiu C; Gastman B; Beitsch P; Rapisuwon S; Glaspy J; McCarron EC; Gupta V; Behl D; Blumenstein B; Peterkin JJ
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599031
[TBL] [Abstract][Full Text] [Related]
19. First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality.
Fogarty GB; Hong A; Dolven-Jacobsen K; Reisse CH; Burmeister B; Haydu LH; Dhillon H; Steel V; Shivalingam B; Drummond K; Vardy J; Nowak A; Hruby G; Scolyer RA; Mandel C; Thompson JF
BMC Res Notes; 2015 May; 8():192. PubMed ID: 25952979
[TBL] [Abstract][Full Text] [Related]
20. Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial.
Ackermann DM; Smit AK; Janda M; van Kemenade CH; Dieng M; Morton RL; Turner RM; Cust AE; Irwig L; Hersch JK; Guitera P; Soyer HP; Mar V; Saw RPM; Low D; Low C; Drabarek D; Espinoza D; Emery J; Murchie P; Thompson JF; Scolyer RA; Azzi A; Lilleyman A; Bell KJL
Trials; 2021 May; 22(1):324. PubMed ID: 33947444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
